Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Puma's Likely Neratinib EU Knockback May Be Temporary

Executive Summary

A positive opinion on the marketing application for Puma's neratinib in the EU is unlikely next month after a recent discussion with regulators failed to satisfy risk-benefit concerns, but more data on controlling diarrhea are expected shortly.


Related Content

Puma's Neratinib Gets CHMP Turnaround But Slow EU Uptake Expected
A Massive First For EU – CAR-T Therapies Kymriah and Yescarta Hoping For CHMP OK
Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns
Decision Time At CHMP: Portola and Aegerion In Spotlight
Lessons Learned: Santhera Will Refile Raxone For DMD In EU Next Year
CHMP Negative On PharmaMar's Aplidin In Multiple Myeloma
Puma's Nerlynx Scores Broad Label Across Adjuvant Breast Cancer Subgroups
Puma May Face Marketing Hurdles Even If Neratinib Wins Final Approval
Takeda's Ninlaro Back In European Myeloma Race After CHMP Turnaround


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts